ARGEN X SE (ARGX)

Argenx stock stays tied to late-stage immunology data and the latest financial update. The company r

Argenx (ARGX) announced the acquisition of Forte Biosciences (FBRX) at $77 per share on July 27. FBRX saw significant price movement beginning June 29, weeks before the public announcement. Both FBRX and ARGX exhibited notable trading activity ahead of the deal, suggesting possible insider ...

The Zacks Rank is a proven model ... of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. argenex SE is currently sporting a Zacks Rank of #2 (Buy)…

I am upgrading Argenx (ARGX)(ARGNF) to BUY from HOLD because of the following reasons: a) continued positive commercial execution, b) label expansion, and c) balance-sheet de-risking, which has increased my confidence ... Lifescience investor focused on non-consensus long-short investment ideas. I f…

argenx stock has delivered a very strong 202.6% return over the past five years, yet its current valuation checks point to a more mixed picture rather than a clear bargain or clear overvaluation. With the share price around US$789.80 and expectations building around its immunology pipeline ...